This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rose, L. Articles by Isenberg, D. Search for Related Content PubMed PubMed Citation Articles by Rose, L. Articles by Isenberg, D. Social Bookmarking                         What's this?

Elevated soluble fas production in SLE correlates with HLA status not with disease activity

Bloomsbury Rheumatology Unit, Division of Rheumatology, Department of Medicine, University College London, Arthur Stanley House, Tottenham Street, London W1P 9PG, Medical Molecular Biology Unit, Department of Molecular Pathology, University College London Medical School, Cleveland Street, London W1P 6DB, UK

DS Latchman

Medical Molecular Biology Unit, Department of Molecular Pathology, University College London Medical School, Cleveland Street, London W1P 6DB, UK

DA Isenberg

Bloomsbury Rheumatology Unit, Division of Rheumatology, Department of Medicine, University College London, Arthur Stanley House, Tottenham Street, London W1P 9PG

Evidence from animal models of lupus suggests that disruption of Fas-mediated apoptotic events may play a role in systemic lupus erythematosus (SLE). The recently described secreted form of Fas (sFas) could interfere with apoptotic events by blockading Fas/Fas ligand interactions. We describe elevated secreted Fas protein in sera from 60 patients with SLE compared with controls but neither sFas protein nor sFas mRNA levels correlated with disease activity. At the mRNA level there is strong evidence that individuals with human leucocyte antigens common in SLE patients have a genetic predisposition for increased secreted Fas production.

Key Words: systemic lupus erythematosus • apoptosis • Fas

Lupus, Vol. 6, No. 9, 717 (1997)
DOI: 10.1177/096120339700600907


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Otsuki, Y. Miura, Y. Nishimura, F. Hyodoh, A. Takata, M. Kusaka, H. Katsuyama, M. Tomita, A. Ueki, and T. Kishimoto Alterations of Fas and Fas-Related Molecules in Patients with Silicosis. Experimental Biology and Medicine, May 1, 2006; 231(5): 522 - 533. [Abstract] [Full Text] [PDF]

				J W. Dieker, J van der Vlag, and J H. Berden Triggers for anti-chromatin autoantibody production in SLE Lupus, December 1, 2002; 11(12): 856 - 864. [Abstract] [PDF]

				M W van der Linden, T van Lopik, L A Aarden, R G J Westendorp, and T W J Huizinga Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives Ann Rheum Dis, March 1, 2001; 60(3): 237 - 241. [Abstract] [Full Text] [PDF]

				M. H Al-Maini, J. D Mountz, H. A Al-Mohri, E. M El-Ageb, B. M Al-Riyami, K. L G Svenson, T. Zhou, and E. R Richens Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus Lupus, February 1, 2000; 9(2): 132 - 139. [Abstract] [PDF]